Slaughter and May and Sullivan & Cromwell are advising on either side of a deal that sees UK-listed drug company Shire buy US biotech group Dyax for $5.9bn (

Slaughter and May and Sullivan & Cromwell are advising on either side of a deal that sees UK-listed drug company Shire buy US biotech group Dyax for $5.9bn (